* Atea Pharmaceuticals Inc reported a quarterly adjusted loss of 75 cents per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of four analysts for the quarter was for a loss of 61 cents per share. Wall Street expected results to range from -63 cents to -57 cents per share.
* Reported revenue was zero; analysts expected zero.
* Atea Pharmaceuticals Inc's reported EPS for the quarter was a loss of 75 cents.
* The company reported a quarterly loss of $63.17 million.
* Atea Pharmaceuticals Inc shares had held steady so far this quarter and gained 32.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $3.50 This summary was machine generated from LSEG data May 14 at 09:49 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.61 -0.75 Missed
Dec. 31 2023 -0.50 -0.47 Beat
Sep. 30 2023 -0.48 -0.40 Beat
Jun. 30 2023 -0.47 -0.34 Beat
Comments